Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERN1 | O75460 | 2/20 | 0.68 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.52 |
| ▸ | HPGD | P15428 | 3/20 | 0.51 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.50 |
| ▸ | TYR | P14679 | 1/20 | 0.50 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29953757 | 1.00 | ERN1 (0.68) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL7031594 | 0.88 | ERN1 (0.78) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL6268566 | 0.86 | ERN1 (0.52) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL10088517 | 0.81 | ERN1 (0.46) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL23442397 | 0.81 | ERN1 (0.73) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL829755 | 0.81 | ERN1 (1.00) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL10331731 | 0.80 | ERN1 (0.45) | ERN1CYP3A4HPGDPOLBKMT2A | |
| SCHEMBL869070 | 0.79 | CYP3A4 (0.48) | ERN1CYP3A4HPGDKMT2AMAPT | |
| SCHEMBL15348517 | 0.79 | ERN1 (0.66) | ERN1CYP3A4HPGDTRIM24TYR | |
| SCHEMBL30294862 | 0.79 | ERN1 (0.96) | ERN1CYP3A4HPGDTRIM24TYR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3624849-B1 | COMBINATION OF AN ASCOCHLORIN DERIVATIVE AND AN IMMUNE CHECKPOINT INHIBITOR FOR TREATING CANCER | HOSHINO TATSUO (JP) | 2025-12-24 | — | — | EP | disclosed |
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | IDORSIA PHARMACEUTICALS LTD (CH) | 2023-12-12 | — | — | US | disclosed |
| EP-3625228-B1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-07-07 | — | — | EP | disclosed |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2021-04-22 | — | — | US | disclosed |
| EP-3625228-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | Idorsia Pharmaceuticals Ltd (CH) | 2020-03-25 | — | — | EP | disclosed |
| CN-110612299-A | Pyrimidine derivatives as PGE2 receptor modulators | 爱杜西亚药品有限公司 | 2019-12-24 | — | — | CN | disclosed |
| WO-2018210988-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | IDORSIA PHARMACEUTICALS LTD (CH) | 2018-11-22 | — | — | WO | disclosed |
| US-8119675-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| US-8119675-B2 | Benzimidazole derivatives | MERCK PATENT GMBH (DE) | 2012-02-21 | — | — | US | disclosed |
| EP-2121627-B1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-08-18 | — | — | EP | disclosed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2008101586-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11839613-B2 | Pyrimidine derivatives as PGE2 receptor modulators | PTGER1, PTGER4, PTGER2 | ERN1 1311/4885CYP3A4 144/4885HPGD 135/4885 |
| US-20210113559-A1 | PYRIMIDINE DERIVATIVES AS PGE2 RECEPTOR MODULATORS | PTGER1, PTGER4, PTGER2 | ERN1 1311/4885CYP3A4 144/4885HPGD 135/4885 |
| US-20100016372-A1 | Benzimidazole Derivatives | GPR119, GLP1R, H1-3 | ERN1 966/4885CYP3A4 651/4885HPGD 4325/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.